Attention: Volunteers who have prior confirmation of celiac disease from blood work or a biopsy. If you meet the following criteria, you may qualify for a clinical research study of an investigational drug. Medical insurance is not necessary.
Continue ReadingThe CeliacShield Study is being conducted to assess the investigational drug latiglutenase and its ability to protect the small intestine of celiac disease patients from gluten exposure.
Continue ReadingCeliac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...